# Semaglutide Effects & Side Effects: What People Report and What to Watch > Semaglutide effects logged plainly: the benefits and side effects people report (anecdotal), plus cited safety cautions — GI intolerance, thyroid warning, lean-mass loss, more. Reported benefits and downsides, clearly labeled anecdotal — then the cited cautions that give them context. ## The short version This page covers Semaglutide effects in two layers. First: what people actually report — the good and the bad. Second: what the published safety record says, with citations. The benefit people describe most is that the constant mental chatter about food (often called "food noise") goes quiet, usually within a week or two. Weight loss and fewer cravings follow. The downside people report most is nausea, often with a distinctive sulfur or "rotten egg" burp, plus bowel changes and early tiredness. Most of it clusters around starting the drug or raising the dose. The reports are real-world experience, not proof. The cautions further down are different: those come from trials and drug-safety data, and they are cited. No doses appear on this page, and nothing here is medical advice. ## What people report These are effects reported by the patient and research-use community — **anecdotal, not clinical evidence**, not verified by controlled trials, and not tied to any dose. **Benefits people report** - **Appetite suppression / quieter "food noise"** (frequently reported). The most common benefit: the background chatter about food goes quiet, often in the first week or two. People say they feel full faster, eat a third to a half of old portions, and stop circling back to the next meal. Many call this the single most life-changing effect. - **Fewer cravings — sugar, sweets, fried and greasy food** (frequently reported). Sweet-tooth and sugar cravings drop sharply or vanish; fried and high-fat foods stop appealing and can turn slightly off-putting. Several describe drifting toward fruit, vegetables, and lighter meals on their own, often within the first weeks. - **Weight loss** (frequently reported). The large majority report losing weight, often steady and substantial over several months, with the pace slowing after the early stretch. Many tie it directly to eating much less rather than to exercise. - **Better blood-sugar control** (commonly reported). Among people using it for type 2 diabetes, a common theme is markedly improved blood-sugar and A1C readings, with fasting numbers and long-term averages dropping into normal ranges, sometimes with steadier daytime energy. - **Reduced desire to drink alcohol** (occasionally reported). A recurring secondary observation: the urge to drink fades along with food cravings, and some people simply lose interest. Patient communities discuss this widely as an unexpected side benefit. It echoes the emerging trial work covered on the [semaglutide and alcohol](/alcohol) page — but the reports themselves remain anecdotal. **Side effects people report** - **Nausea, sometimes with vomiting** (frequently reported). The single most reported side effect, named by roughly a third of reviewers; a subset escalates to vomiting at its worst. It peaks in the first weeks and after each dose increase, often easing within a week or two, and flares after overeating or fatty food. Many manage it with smaller, lighter meals and more water. - **Sulfur / "egg" burps** (commonly reported). Foul-smelling burps people compare to rotten eggs or sulfur, often after a dose increase, sometimes lasting hours to weeks, frequently with bloating and a sense of food sitting too long. Many describe them as embarrassing and far more common than official lists suggest; some find they fade with time. - **Bowel changes — constipation and diarrhea** (commonly reported). Both extremes show up, sometimes alternating. Constipation appears as hard, infrequent stools (some reach for laxatives); diarrhea is worse in the days after a dose or after rich food. A few note the constipation partly reflects eating very little. - **Acid reflux / heartburn** (occasionally reported). Reflux, heartburn, and indigestion, sometimes described as the worst heartburn they have had, often alongside burping and bloating and tracking with dose increases. - **Fatigue / tiredness early on** (commonly reported). Low energy, especially the day or two after an injection and during early weeks; often described as feeling wiped out, usually easing with time. - **Food aversions, taste changes, over-suppressed appetite** (occasionally reported). Active aversions to fatty, fried, or meaty food; a metallic taste; heightened, unpleasant smell sensitivity that can itself trigger nausea (people liken it to morning sickness). For a few, appetite is suppressed so far they must remind themselves to eat. - **Hair shedding and facial gauntness from rapid weight loss** (sometimes reported). A smaller group reports extra hair shedding a few months in, plus a thinner, more hollow face. Both are widely attributed to losing weight fast rather than the drug, and the shedding is usually described as temporary. - **Headaches and dizziness** (occasionally reported). Often early in a new dose and linked to under-drinking or under-eating; many say hydration helps. - **Injection-site reactions** (sometimes reported). Mild redness, itching, a small bump, or tenderness where injected — generally minor and short-lived. ## Safety & cautions This is the cited layer. Each caution below comes from trials or drug-safety data, not from anecdote. #### Semaglutide side effects The semaglutide side effects that dominate are gastrointestinal. Gastrointestinal intolerance is the dominant adverse effect and the leading reason people stop. A pooled analysis of the weight-management program found nausea, vomiting, diarrhea, and constipation were mostly mild-to-moderate and transient, concentrated around dose escalation [16]; a dedicated safety review reported nausea in roughly one-third of patients, and real-world pharmacovigilance reporting is likewise dominated by GI events [5][18]. This is mechanistic, not mysterious: slowed gastric emptying is part of how the drug works [16]. **Thyroid (boxed warning).** GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors, derived from rodent studies at supratherapeutic exposures. A dedicated assessment concluded human data do not establish a clear increase in medullary or other thyroid cancer attributable to semaglutide — the signal is unconfirmed in humans — yet a personal or family history of medullary thyroid carcinoma or MEN-2 is treated as a contraindication on the strength of the rodent finding [17][5]. **Acute pancreatitis (class warning).** Pancreatitis is a recognized class warning, and treatment is conventionally stopped if it is suspected. The same safety review notes that pancreatic-cancer signals remain ones for which definitive conclusions cannot yet be drawn owing to low incidence — a precautionary caution, not a demonstrated quantitative risk [5]. **Gallbladder and biliary disease.** A safety review found an increased risk of cholelithiasis (gallstones) versus placebo, attributed largely to the rate and magnitude of weight loss rather than direct drug toxicity — but the increase is a real trial and pharmacovigilance finding, not theoretical [5]. **Pre-existing diabetic retinopathy with rapid glucose correction.** In SUSTAIN-6, diabetic-retinopathy complications were significantly more frequent on semaglutide (HR 1.76; 95% CI 1.11-2.78), concentrated in people with pre-existing retinopathy whose HbA1c fell rapidly. The leading interpretation is early worsening from the speed of glucose correction, not direct retinal toxicity; monitoring is advised when glucose is corrected fast [2][5]. **Loss of lean (muscle) mass.** A body-composition substudy reported that the weight lost includes a meaningful proportion of lean mass, not just fat — raising a sarcopenia concern, especially in older adults, and motivating research into protein intake and resistance training [13]. The lean-mass loss is observed in trials; the downstream sarcopenia risk is a mechanistically reasoned extrapolation. More on the [muscle-loss page](/muscle-loss). **Weight regain after stopping.** Stopping is followed by substantial regain. In the STEP 1 extension, participants regained a mean of roughly 11.6 percentage points of body weight within a year and cardiometabolic gains reverted toward baseline [19]; the STEP 4 withdrawal design showed regain after switching to placebo [20]. This frames the drug as a chronic, not curative, intervention. **Hair shedding (telogen effluvium).** A pharmacovigilance analysis flagged an alopecia reporting signal with semaglutide and tirzepatide [14], and a separate dermatology study linked telogen effluvium — reversible diffuse shedding — to the magnitude and rate of weight loss [15]. The signal is most consistent with rapid-weight-loss shedding rather than direct toxicity. **Pregnancy (contraindicated).** Semaglutide is contraindicated in pregnancy per labeling. Because the half-life is about a week, with effectively complete clearance only about five weeks after the last dose, label guidance advises stopping well in advance of a planned pregnancy (commonly cited as roughly two months) [11]. The half-life arithmetic is documented; the contraindication is a regulatory statement. **Drug interactions during titration.** A systematic review found the delayed gastric emptying generally does not cause clinically significant interactions, but advised monitoring narrow-therapeutic-index oral drugs, especially during dose escalation — overall interaction risk characterized as low [22]. ## Then and now Semaglutide is recent. It first reached FDA approval for type 2 diabetes in 2017, with an oral once-daily form following in 2019-2020 and a chronic weight-management use in 2021 [1][11]. Cardiovascular-outcome evidence (SELECT) read out in 2023 [3] and kidney-outcome evidence (FLOW) in 2024 [6], with the matching heart and chronic-kidney-disease uses approved in 2024-2025 and a fatty-liver (MASH) use in 2025. During a federally declared shortage from roughly 2022 to early 2025, compounding pharmacies were permitted to make semaglutide; that pathway was curtailed once the shortage was declared resolved in early 2025 [11]. --- A terminal-clean log of the semaglutide trial record — the STEP, SELECT, SUSTAIN-6 and FLOW figures committed to source, the emerging alcohol-craving lines flagged as early, and the unconfirmed signals left in plain view; no clinic behind the console, no script written, and nothing here dosed, compounded, or sold.